UC Causal Mechanism Digest 005 — ALP, Cholesterol, Gut-Liver-Lipid Axis

Why this digest matters

Paul observes two unusually objective patterns:

• cholesterol numbers appear to rise during UC/proctitis flares and improve when symptoms are controlled;
• ALP tends to run high and appears to rise with symptoms/calprotectin, then fall when symptoms improve.

This batch asks whether those signals belong in the central UC/proctitis causal model, and what they might mean.

Bottom line for the central theory

The ALP/cholesterol pattern should be kept as a high-priority objective biomarker branch, but with important caveats.

Working model:

Distal UC/proctitis flare / barrier failure / dysbiosis
      ↓
more gut-derived inflammatory signaling: LPS, cytokines, altered bile acids, permeability
      ↓
gut-liver axis activation + bile/lipid metabolism shifts
      ↓
possible changes in ALP/GGT/bilirubin/AST/ALT and cholesterol/lipoproteins

The most important practical split is:

Is Paul’s ALP mainly liver/bile duct ALP, bone ALP, intestinal ALP, or mixed?

Without ALP isoenzymes plus GGT/bilirubin/AST/ALT context, elevated ALP is not interpretable enough to assign one cause.

Paul’s existing notes absorbed

From the Notion export and wiki:

• Paul wants to know why ALP is elevated for so long.
• Paul has considered PSC screening because UC can co-occur with bile-duct inflammation.
• Paul wants an ALP isoenzyme panel.
• Paul wants to confirm gallbladder/liver function and has asked about biliary dyskinesia.
• Family cholesterol numbers are high.
• Cholesterol appears to spike during flares and fall when symptoms are controlled.
• ALP appears to track symptoms/calprotectin.

Source-by-source synthesis

1. IBD lipid meta-analysis: IBD often shows lower serum lipids, especially with active disease

Source: Chen et al. 2023. “Association of serum lipids with inflammatory bowel disease: a systematic review and meta-analysis.” PMID 37692785.
Class: systematic review/meta-analysis.

Key findings:

• 53 studies included.
• Compared with healthy controls, IBD patients had lower:
  • total cholesterol;
  • HDL-C;
  • LDL-C.
• Active IBD and non-mild UC tended to have lower TC/LDL than inactive/mild disease.
• Authors conclude serum lipids are lower in IBD and negatively associated with disease severity.

Central-theory implication:

• This does not neatly match Paul’s reported cholesterol rise during flares.
• That mismatch is valuable: Paul’s pattern may reflect family/genetic lipid risk, dietary changes during flares, medication effects, thyroid/sleep/metabolic factors, fasting/weight changes, or a different inflammatory lipid-response pattern.
• We should not assume flare = high cholesterol universally.

2. Intestinal alkaline phosphatase: ALP is not just a liver marker; intestinal ALP detoxifies LPS and supports barrier function

Sources: Kühn et al. 2021 PMID 34722721; Santos et al. 2022 DOI 10.3390/microorganisms10040746; 2026 Food & Function PMID 42065513.
Class: mechanistic reviews.

Key findings:

• Intestinal alkaline phosphatase (IAP/IALP) is a brush-border enzyme made by enterocytes.
• IAP supports gut homeostasis through:
  • LPS detoxification;
  • tight-junction/barrier support;
  • microbiome regulation;
  • lipid absorption and luminal homeostasis.
• LPS detoxification is especially important: IAP dephosphorylates lipid A, making LPS far less inflammatory.
• IAP activity may be influenced by diet, fiber/prebiotics, butyrate/SCFAs, probiotics, Mediterranean dietary patterns, and other factors.

Central-theory implication:

• Paul’s serum ALP is not the same as fecal/intestinal ALP activity, but this source opens an important conceptual branch: alkaline phosphatase biology is tied to barrier/LPS/endotoxin control.
• If Paul’s elevated ALP includes an intestinal fraction, it could reflect gut epithelial stress or compensatory barrier signaling; if liver fraction, it points more toward cholestasis/bile ducts/liver.
• This supports the plan to ask for ALP isoenzymes and contextual labs.

3. PSC and IBD: cholestatic enzymes in UC deserve clinician-guided evaluation, not panic

Sources: AASLD clinical pearl; 2024 PSC diagnostic criteria PMID 40504416; PSC gut-liver review PMID 41227212.
Class: clinical guidance/review.

Key findings:

• PSC is strongly associated with IBD, especially UC, but remains uncommon overall.
• PSC suspicion typically involves a cholestatic pattern: elevated ALP and/or GGT, sometimes bilirubin, fatigue/pruritus/RUQ pain, and exclusion of other causes.
• MRCP/MRC is preferred first-line imaging when PSC is suspected; ERCP is generally not first-line for diagnosis.
• Small-duct PSC can have normal cholangiography and requires biopsy in specific contexts.
• PSC pathogenesis is heavily gut-liver-axis framed: barrier failure, microbial translocation, dysbiosis, altered bile acids, and immune trafficking.

Central-theory implication:

• Paul’s persistent/high ALP plus UC context makes PSC/bile-duct questions reasonable for clinician discussion.
• But ALP alone is insufficient; GGT, bilirubin, AST/ALT, symptoms, imaging history, and isoenzyme fraction matter.
• This branch should be framed as “screen thoughtfully,” not “assume PSC.”

4. Bile acid–gut microbiota axis: bile acids are immune/barrier/microbiome signals, not just fat digestion

Source: Yang et al. 2021. “Bile Acid–Gut Microbiota Axis in Inflammatory Bowel Disease.” PMID 34579027 / DOI 10.3390/nu13093143.
Class: mechanistic review.

Key findings:

• In IBD, microbial diversity is reduced, Firmicutes/bile-acid-transforming bacteria decline, and Proteobacteria can expand.
• Dysbiosis can block bile acid transformation, increasing primary/conjugated bile acids and reducing secondary bile acids.
• Bile acid receptors including FXR, TGR5, PXR, and VDR regulate barrier function, immunity, and metabolism.
• Therapeutic research includes diets, probiotics, prebiotics, engineered bacteria, FMT, and UDCA, but this is not a recommendation.

Central-theory implication:

• Bile acid metabolism is a plausible bridge between dysbiosis, liver/gallbladder questions, lipid metabolism, diarrhea/urgency, barrier function, and inflammation.
• For Paul’s constipation/proctitis pattern, bile acids may still matter, but the next step is evidence mapping rather than assuming bile acid deficiency/excess.

5. PSC gut-liver axis: barrier failure can send microbial products to the liver

Source: 2025 PSC gut-liver axis review PMID 41227212.
Class: mechanistic review.

Key findings:

• PSC pathogenesis is framed around intestinal barrier failure, microbial translocation through portal circulation, dysbiosis, bile acid signaling, and immune activation.
• PSC-IBD association supports the idea that gut inflammation and liver/bile-duct inflammation can be coupled.

Central-theory implication:

• This strengthens the central model’s “gut-liver-lipid axis” node: gut barrier failure may not stay local.
• Paul’s ALP/lipid observations could be downstream signals of systemic/gut-liver communication.

Sources browsed and new takeaways

Source	URL/platform	Class	Why browsed	Main new takeaway	Novelty status	Affected page/theory
Serum lipids in IBD meta-analysis	https://pmc.ncbi.nlm.nih.gov/articles/PMC10484721/	systematic-review/meta-analysis	Test Paul’s cholesterol-flare pattern against literature	Population-level IBD often shows lower TC/LDL/HDL, especially with active disease; Paul’s high-with-flare pattern is not the default	contradicts_existing/personal_pattern	central theory gut-liver-lipid node
Intestinal alkaline phosphatase barrier review	https://pmc.ncbi.nlm.nih.gov/articles/PMC8543353/	mechanistic-review	Explore ALP as gut barrier/LPS biology	IAP detoxifies LPS and supports barrier/microbiome; serum ALP needs isoenzyme context	new_to_wiki	ALP mechanism branch
IALP intestinal barrier review	https://www.mdpi.com/2076-2607/10/4/746	mechanistic-review	Clarify IALP functions	IALP is linked to barrier integrity, LPS detoxification, microbiota, and possible fecal biomarker use	new_to_wiki	ALP/IAP page
PSC AASLD clinical pearl	https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/primary-sclerosing-cholangitis-management-tips-and	clinical-guidance	Understand ALP/GGT/MRCP relevance	PSC suspicion uses cholestatic labs; MRCP is preferred diagnostic imaging after evaluation	safety_signal	clinician questions
2024 PSC diagnostic criteria	https://pmc.ncbi.nlm.nih.gov/articles/PMC12450801/	clinical-guidance/criteria	Clarify PSC diagnosis	MRC/MRCP emphasized; small-duct PSC and IBD evaluation matter	new_to_wiki	clinician questions
PSC gut-liver axis review	https://pmc.ncbi.nlm.nih.gov/articles/PMC12608333/	mechanistic-review	Connect UC/IBD to bile ducts/liver	Barrier failure, microbial translocation, dysbiosis, bile acids, and immune trafficking may drive PSC	new_to_wiki	gut-liver mechanism page
Bile acid–gut microbiota axis in IBD	https://www.mdpi.com/2072-6643/13/9/3143	mechanistic-review	Map bile-acid branch	IBD dysbiosis can alter primary/secondary bile acid balance and immune/barrier receptor signaling	new_to_wiki	bile acid branch
Raw PubMed batch	raw/papers/2026-06-18-uc-alp-cholesterol-gut-liver-digest-005/pubmed-abstracts.md	provenance	Capture metadata/abstracts	24 records saved; DOI fields corrected after parser issue	new_to_wiki	raw provenance
Paul’s Notion/source queue notes	conditions/ulcerative-colitis/source-digestion-queue.md	personal/source-queue	Capture personal ALP/PSC/lipid questions	ALP isoenzymes, PSC scan question, gallbladder/liver function, cholesterol flare pattern are all already in Paul’s notes	reinforces_existing	key insights/personal history

Reviewed but no major new data

Source	Status	Note
Older lipid abnormality overview	low priority	Useful background but superseded by 2023 systematic review/meta-analysis for the core lipid pattern.
General PSC consumer summaries	reinforced_existing	Repeated that ALP/GGT/bilirubin and MRCP matter; not promoted over AASLD/criteria sources.
Broad gut-liver/NAFLD records in PubMed batch	not promoted yet	Relevant to systemic metabolism, but not specific enough for UC/proctitis digest 005.
Biliary dyskinesia anecdotal Reddit link	pending anecdote review	Not digested in this clinical/mechanistic batch; may be useful later for lived-experience context only.

Updated causal interpretation

Digest 005 changes the model in two ways:

1. ALP becomes a split-signal, not a single clue. Elevated ALP could be liver/bile duct, bone, intestinal, or mixed. The next correct research/clinical move is fractionation/context, not a single causal claim.
2. Cholesterol pattern becomes a personal-outlier clue. Population IBD literature often shows lower lipids with activity. Paul’s rise-during-flare pattern may therefore be especially worth tracking, but it may reflect individualized metabolism, family risk, sleep/stress, diet changes, thyroid, liver/bile changes, medication/supplement changes, or lab timing.

Clinician / testing questions generated

Not medical advice; clinician-discussion list:

• For persistent or flare-tracking ALP, should Paul get ALP isoenzymes or fractionated ALP?
• When ALP is high, what are GGT, bilirubin, AST, ALT, albumin, platelets, INR, CRP/ESR, and fecal calprotectin?
• Is the ALP pattern cholestatic enough to justify hepatology review or MRCP/MRC discussion?
• Has PSC been reasonably excluded, and is small-duct PSC relevant if cholestatic labs persist with normal imaging?
• Could bone sources explain ALP: vitamin D, PTH, bone-specific ALP, recent exercise/injury, thyroid/parathyroid status?
• Do lipid changes correlate with fasting status, weight, diet, flare severity, calprotectin, thyroid markers, sleep, medications, supplements, or liver enzymes?
• Should ApoB, LDL-P, Lp(a), hs-CRP, thyroid, A1c/insulin, and liver markers be tracked during remission vs flare?
• Could fecal/intestinal ALP activity ever be useful, or is this still research-only?

Next research batch recommendation

Next best batch: mucus phosphatidylcholine / delayed-release PC formulations or Dr. Pravda/Roediger/redox theory. The ALP/lipid branch is now framed enough to guide clinician questions, but the strongest causal-remedy branch may be mucus PC + redox/barrier repair.